High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients
M Stendahl, L Rydén, B Nordenskjöld… - Clinical Cancer …, 2006 - AACR
M Stendahl, L Rydén, B Nordenskjöld, PE Jönsson, G Landberg, K Jirström
Clinical Cancer Research, 2006•AACRPurpose: Tamoxifen has long been the drug of choice in adjuvant endocrine therapy of
steroid hormone receptor–positive breast cancer, and it still remains important due to its well-
documented beneficial effect. Hormone receptor status is often reported as “positive” or
“negative” using 10% positive nuclei as a cutoff. In this study, we aimed to assess whether a
further subclassification of hormone receptor status could enhance the treatment predictive
value. Experimental Design: The immunohistochemical expression of estrogen receptor …
steroid hormone receptor–positive breast cancer, and it still remains important due to its well-
documented beneficial effect. Hormone receptor status is often reported as “positive” or
“negative” using 10% positive nuclei as a cutoff. In this study, we aimed to assess whether a
further subclassification of hormone receptor status could enhance the treatment predictive
value. Experimental Design: The immunohistochemical expression of estrogen receptor …
Abstract
Purpose: Tamoxifen has long been the drug of choice in adjuvant endocrine therapy of steroid hormone receptor–positive breast cancer, and it still remains important due to its well-documented beneficial effect. Hormone receptor status is often reported as “positive” or “negative” using 10% positive nuclei as a cutoff. In this study, we aimed to assess whether a further subclassification of hormone receptor status could enhance the treatment predictive value.
Experimental Design: The immunohistochemical expression of estrogen receptor (ER) and progesterone receptor (PR) was quantified in tissue microarrays with tumors from 500 premenopausal breast cancer patients previously included in a randomized trial of adjuvant tamoxifen compared with an untreated control group.
Results: Our findings show a gradually increasing tamoxifen effect in tumors with >10% ER-positive nuclei. However, when analyzing tamoxifen response according to various PR fractions, we found that it was primarily patients with tumors showing >75% PR-positive nuclei that responded to tamoxifen treatment, with an improved recurrence-free [relative risk, 0.42 (0.25-0.70); P = 0.001] as well as overall [relative risk, 0.49 (0.28-0.84); P = 0.010] survival.
Conclusions: Adjuvant tamoxifen improved recurrence-free and overall survival for premenopausal patients with tumors showing >75% PR-positive nuclei. No effect could be shown in tumors with fewer PR-positive nuclei. The PR was a stronger predictor of treatment response than the ER. Based on these findings, we suggest the implementation of a fractioned rather than dichotomized immunohistochemical evaluation of hormone receptors in clinical practice, possibly with greater emphasis on the PR than the ER.
AACR